eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2010
vol. 14
 
Share:
Share:
abstract:
Review paper

BCL-XL as a tumour prognostic factor?

Bożenna Kaczmarek-Borowska
,
Szymon Zmorzyński
,
Agata Filip
,
Jacek Wojcierowski

Współczesna Onkologia (2010) vol. 14; 1 (7–10)
Online publish date: 2010/02/25
View full text Get citation
 
PlumX metrics:
BCL-2 family proteins are key regulators of programmed cell death or apoptosis, which is implicated in many human diseases, particularly cancer. The BCL-2 family includes both anti- and pro-apoptotic proteins with opposing biological functions in either inhibiting or promoting cell death. High expression of anti-apoptotic members such as BCL-XL commonly found in human cancer contributes to neoplastic cell expansion and interferes with the therapeutic action of many chemotherapeutic drugs. The functional blockade of BCL-XL could either restore the apoptotic process in tumour cells or sensitize these tumours for chemo- and radiotherapies. Increased expression of BCL-XL protein has been reported in many tumours: breast cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer, ovarian cancer and in lymphomas, leukaemias, melanomas and head and neck cancers. The results show that BCL-XL overexpression may be a poor prognostic factor in non-small cell lung cancer and colon cancer, which means bad prognosis and resistance to chemotherapy.
keywords:

BCL-XL, BCL-2 family proteins, tumour, apoptosis

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.